Final answer:
The correct antibody against the EGF receptor for treating colon cancer is cetuximab. Trastuzumab targets HER2 in breast cancer, while rituximab and bevacizumab target other molecules.
Step-by-step explanation:
The antibody directed against the EGF receptor of colon cancer is known as cetuximab. This monoclonal antibody targets the Epidermal Growth Factor Receptor (EGFR), which is often overexpressed in types of non-small cell lung cancer and colorectal cancer. By inhibiting the function of the EGFR, which is involved in the growth and spread of cancer cells, cetuximab helps to control the progression of the disease. It should be noted that while trastuzumab is a monoclonal antibody, it targets the HER2 (human epidermal growth factor receptor 2) and is used in treating breast cancer, not colon cancer. Other antibodies mentioned, such as rituximab and bevacizumab, have different targets: rituximab targets CD20 on B cells, and bevacizumab targets vascular endothelial growth factor (VEGF), respectively, and neither is specifically an anti-EGFR monoclonal antibody for colon cancer.